Ligand for herpes simplex virus entry mediator and methods of use
CA 2406132 C · Owner: Ware, Carl F. · Inventors: Ware, Carl F.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A novel polypeptide ligand, p30, or LIGHT for herpes virus entry mediator, HVEM, is provided. p30 is useful for modulating immune responses and in inhibiting infection and/or subsequent proliferation by herpes virus. HVEM fusion proteins are also provided. Methods for treating subjects with lymphoid cell disorders, tumors, autoimmune diseases inflammatory disorders of those , having or suspected of having a herpes virus infection utilizing p30 and the , fusion proteins of the invention are also provided.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 11, 2001 and granted July 3, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended April 11, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 11, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.